nach oben

Journal of Neurology

Erschienen in:

01.08.2009

Non-motor symptoms in Parkinson’s disease

verfasst von: Ariane Park, Mark Stacy

Erschienen in: Journal of Neurology | Sonderheft 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Parkinson’s disease is a hypokinetic movement disorder with cardinal motor features of bradykinesia, resting tremor and rigidity. However, non-motor symptoms, such as cognitive, neuropsychiatric, sleep, autonomic and sensory disturbances are gaining increasing attention. These non-motor symptoms may be intrinsic to the disease pathology or may be results of treatment with dopaminergic agents. Given that most, if not all, patients with Parkinson’s disease will experience non-motor symptoms, it is important to be sensitive to these phenomena, especially since some non-motor signs may precede motor impairment. Treatment may include interventions independent of traditional, dopaminergic anti-Parkinson therapy or may be tailored to increase or reduce dopamine responsiveness of the symptom.

Anonymous (1999) Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. The Parkinson Study Group. N Engl J Med 340:757–763

Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sorensen P (2001) Risk of dementia in Parkinson’s disease: a community-based, prospective study. Neurology 56:730–736PubMed

Aarsland D, Laake K, Larsen JP, Janvin C (2002) Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 72:708–712PubMedCrossRef

Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J (2003) Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson’s disease. Mov Disord 18:287–293PubMedCrossRef

Boeve BF, Dickson DW, Olson EJ, Shepard JW, Silber MH, Ferman TJ, Ahlskog JE, Benarroch EE (2007) Insights into REM sleep behavior disorder pathophysiology in brainstem-predominant Lewy body disease. Sleep Med 8:60–64PubMedCrossRef

Bohnen NI, Kaufer DI, Ivanco LS, Lopresti B, Koeppe RA, Davis JG, Mathis CA, Moore RY, DeKosky ST (2003) Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 60:1745–1748PubMedCrossRef

Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211PubMedCrossRef

Brandt-Christensen M, Kvist K, Nilsson FM, Andersen PK, Kessing LV (2007) Treatment with antiparkinson and antidepressant drugs: a register-based, pharmaco-epidemiological study. Mov Disord 22:2037–2042PubMedCrossRef

Breier A, Sutton VK, Feldman PD, Kadam DL, Ferchland I, Wright P, Friedman JH (2002) Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease. Biol Psychiatry 52:438–445PubMedCrossRef

10.

Brunton S, Kuritzky L (2005) Recent developments in the management of overactive bladder: focus on the efficacy and tolerability of once daily solifenacin succinate 5 mg. Curr Med Res Opin 21:71–80PubMedCrossRef

11.

Brusa L, Petta F, Pisani A, Moschella V, Iani C, Stanzione P, Miano R, Finazzi-Agro E (2007) Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease. Neurology 68:1455–1459PubMedCrossRef

12.

Cersosimo MG, Benarroch EE (2008) Neural control of the gastrointestinal tract: implications for Parkinson disease. Mov Disord 23:1065–1075PubMedCrossRef

13.

Comella CL, Tanner CM, Ristanovic RK (1993) Polysomnographic sleep measures in Parkinson’s disease patients with treatment-induced hallucinations. Ann Neurol 34:710–714PubMedCrossRef

14.

Cummings JL (1992) Depression and Parkinson’s disease: a review. Am J Psychiatry 149:443–454PubMed

15.

de Groat WC (2006) Integrative control of the lower urinary tract: preclinical perspective. Br J Pharmacol 147(Suppl 2):S25–S40PubMedCrossRef

16.

Degen L, Petrig C, Studer D, Schroller S, Beglinger C (2005) Effect of tegaserod on gut transit in male and female subjects. Neurogastroenterol Motil 17:821–826PubMedCrossRef

17.

Dell’Agnello G, Ceravolo R, Nuti A, Bellini G, Piccinni A, D’Avino C, Dell’Osso L, Bonuccelli U (2001) SSRIs do not worsen Parkinson’s disease: evidence from an open-label, prospective study. Clin Neuropharmacol 24:221–227PubMedCrossRef

18.

Dickson DW, Fujishiro H, DelleDonne A, Menke J, Ahmed Z, Klos KJ, Josephs KA, Frigerio R, Burnett M, Parisi JE, Ahlskog JE (2008) Evidence that incidental Lewy body disease is pre-symptomatic Parkinson’s disease. Acta Neuropathol 115:437–444PubMedCrossRef

19.

Diederich NJ, Raman R, Leurgans S, Goetz CG (2002) Progressive worsening of spatial and chromatic processing deficits in Parkinson disease. Arch Neurol 59:1249–1252PubMedCrossRef

20.

Eichhorn TE, Oertel WH (2001) Macrogol 3350/electrolyte improves constipation in Parkinson’s disease and multiple system atrophy. Mov Disord 16:1176–1177PubMedCrossRef

21.

Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R (2004) Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 351:2509–2518PubMedCrossRef

22.

Factor SA, Feustel PJ, Friedman JH, Comella CL, Goetz CG, Kurlan R, Parsa M, Pfeiffer R (2003) Longitudinal outcome of Parkinson’s disease patients with psychosis. Neurology 60:1756–1761PubMed

23.

Fenelon G (2008) Psychosis in Parkinson’s disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms. CNS Spectr 13:18–25PubMed

24.

Friedman JH, Berman RM, Goetz CG, Factor SA, Ondo WG, Wojcieszek J, Carson WH, Marcus RN (2006) Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson’s disease. Mov Disord 21:2078–2081PubMedCrossRef

25.

Frieling H, Hillemacher T, Ziegenbein M, Neundorfer B, Bleich S (2007) Treating dopamimetic psychosis in Parkinson’s disease: structured review and meta-analysis. Eur Neuropsychopharmacol 17:165–171PubMedCrossRef

26.

Gagnon JF, Postuma RB, Montplaisir J (2006) Update on the pharmacology of REM sleep behavior disorder. Neurology 67:742–747PubMedCrossRef

27.

Goetz CG, Blasucci LM, Leurgans S, Pappert EJ (2000) Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 55:789–794PubMed

28.

Goetz CG, Pappert EJ, Blasucci LM, Stebbins GT, Ling ZD, Nora MV, Carvey PM (1998) Intravenous levodopa in hallucinating Parkinson’s disease patients: high-dose challenge does not precipitate hallucinations. Neurology 50:515–517PubMed

29.

Hussain IF, Brady CM, Swinn MJ, Mathias CJ, Fowler CJ (2001) Treatment of erectile dysfunction with sildenafil citrate (Viagra) in Parkinsonism due to Parkinson’s disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 71:371–374PubMedCrossRef

30.

Jankovic J, Gilden JL, Hiner BC, Kaufmann H, Brown DC, Coghlan CH, Rubin M, Fouad-Tarazi FM (1993) Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med 95:38–48PubMedCrossRef

31.

Kapoor S (2008) Management of constipation in the elderly: emerging therapeutic strategies. World J Gastroenterol 14:5226–5227PubMedCrossRef

32.

Katzenschlager R, Zijlmans J, Evans A, Watt H, Lees AJ (2004) Olfactory function distinguishes vascular parkinsonism from Parkinson’s disease. J Neurol Neurosurg Psychiatry 75:1749–1752PubMedCrossRef

33.

Kaufmann H (2006) The discovery of the pressor effect of DOPS and its blunting by decarboxylase inhibitors. J Neural Transm Suppl 47:7–484

34.

Kulisevsky J, Pagonabarraga J, Pascual-Sedano B, Gironell A, Garcia-Sanchez C, Martinez-Corral M (2008) Motor changes during sertraline treatment in depressed patients with Parkinson’s disease. Eur J Neurol 15:953–959PubMedCrossRef

35.

Kurlan R, Cummings J, Raman R, Thal L (2007) Quetiapine for agitation or psychosis in patients with dementia and Parkinsonism. Neurology 68:1356–1363PubMedCrossRef

36.

Lees AJ, Smith E (1983) Cognitive deficits in the early stages of Parkinson’s disease. Brain 106(Pt 2):257–270PubMedCrossRef

37.

Leroi I, Brandt J, Reich SG, Lyketsos CG, Grill S, Thompson R, Marsh L (2004) Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson’s disease. Int J Geriatr Psychiatry 19:1–8PubMedCrossRef

38.

Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA (1997) Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension: a randomized, double-blind multicenter study. Midodrine Study Group. JAMA 277:1046–1051PubMedCrossRef

39.

Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K, Shulman LM, Gronseth G, Weiner WJ (2006) Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66:996–1002PubMedCrossRef

40.

Negre-Pages L, Regragui W, Bouhassira D, Grandjean H, Rascol O (2008) Chronic pain in Parkinson’s disease: the cross-sectional French DoPaMiP survey. Mov Disord 23:1361–1369PubMedCrossRef

41.

Ondo WG, Perkins T, Swick T, Hull KL Jr, Jimenez JE, Garris TS, Pardi D (2008) Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study. Arch Neurol 65:1337–1340PubMedCrossRef

42.

Ouslander JG (2004) Management of overactive bladder. N Engl J Med 350:786–799PubMedCrossRef

43.

Poewe W, Wolters E, Emre M, Onofrj M, Hsu C, Tekin S, Lane R (2006) Long-term benefits of rivastigmine in dementia associated with Parkinson’s disease: an active treatment extension study. Mov Disord 21:456–461PubMedCrossRef

44.

Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C (2007) Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ duration. Mov Disord 22:313–318PubMedCrossRef

45.

Ravina B, Putt M, Siderowf A, Farrar JT, Gillespie M, Crawley A, Fernandez HH, Trieschmann MM, Reichwein S, Simuni T (2005) Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 76:934–939PubMedCrossRef

46.

Remy P, Doder M, Lees A, Turjanski N, Brooks D (2005) Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128:1314–1322PubMedCrossRef

47.

Sahai A, Khan MS, Arya M, John J, Singh R, Patel HR (2006) The overactive bladder: review of current pharmacotherapy in adults. Part 2: treatment options in cases refractory to anticholinergics. Expert Opin Pharmacother 7:529–538PubMedCrossRef

48.

Schenck CH, Bundlie SR, Mahowald MW (1996) Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 46:388–393PubMed

49.

Schestatsky P, Kumru H, Valls-Sole J, Valldeoriola F, Marti MJ, Tolosa E, Chaves ML (2007) Neurophysiologic study of central pain in patients with Parkinson disease. Neurology 69:2162–2169PubMedCrossRef

50.

Seeman P, Caruso C, Lasaga M (2008) Memantine agonist action at dopamine D2High receptors. Synapse 62:149–153PubMedCrossRef

51.

Stacy M (1999) Managing late complications of Parkinson’s disease. Med Clin North Am 83:469–481

52.

Stacy M (2002) Sleep disorders in Parkinson’s disease: epidemiology and management. Drugs Aging 19:733–739PubMedCrossRef

53.

Stamey W, Davidson A, Jankovic J (2008) Shoulder pain: a presenting symptom of Parkinson disease. J Clin Rheumatol 14:253–254PubMedCrossRef

54.

Uc EY, Rizzo M, Anderson SW, Qian S, Rodnitzky RL, Dawson JD (2005) Visual dysfunction in Parkinson disease without dementia. Neurology 65:1907–1913PubMedCrossRef

55.

Verbaan D, van Rooden SM, Visser M, Marinus J, van Hilten JJ (2008) Nighttime sleep problems and daytime sleepiness in Parkinson’s disease. Mov Disord 23:35–41PubMedCrossRef

56.

Wesnes KA, McKeith I, Edgar C, Emre M, Lane R (2005) Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology 65:1654–1656PubMedCrossRef

57.

Yamamoto T, Sakakibara R, Hashimoto K, Nakazawa K, Uchiyama T, Liu Z, Ito T, Hattori T (2005) Striatal dopamine level increases in the urinary storage phase in cats: an in vivo microdialysis study. Neuroscience 135:299–303PubMedCrossRef

58.

Zangaglia R, Martignoni E, Glorioso M, Ossola M, Riboldazzi G, Calandrella D, Brunetti G, Pacchetti C (2007) Macrogol for the treatment of constipation in Parkinson’s disease. A randomized placebo-controlled study. Mov Disord 22:1239–1244PubMedCrossRef

Titel: Non-motor symptoms in Parkinson’s disease
verfasst von: Ariane Park
Mark Stacy
Publikationsdatum: 01.08.2009
Verlag: D. Steinkopff-Verlag
Erschienen in: Journal of Neurology / Ausgabe Sonderheft 3/2009
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-009-5240-1

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

18.04.2024 | Spinale Muskelatrophien | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Non-motor symptoms in Parkinson’s disease

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Manche Gestagene können das Risiko für Meningeome erhöhen

Parkinson: Größere Studie bestätigt Genauigkeit von Hauttest

Simple Kortisontherapie stoppt primär progrediente Aphasie

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 3/2009

Management of non-motor complications in Parkinson’s disease

17th Symposium on the Treatment of Parkinson’s Disease

Foreword

Formation and development of Lewy pathology: a critical update

Neurotoxic conversion of β-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies?

Axonal regeneration and neural network reconstruction in mammalian CNS

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Manche Gestagene können das Risiko für Meningeome erhöhen

Parkinson: Größere Studie bestätigt Genauigkeit von Hauttest

Simple Kortisontherapie stoppt primär progrediente Aphasie

Update Neurologie